Last updated: March 12, 2026
What is the scope of patent MX392313?
Mexico patent MX392313 protects a pharmaceutical invention related to a specific formulation or method. The patent's scope is defined by its claims, which specify the proprietary subject matter. The patent application was filed on March 4, 2019, and granted on March 4, 2022. It covers a novel composition formulated for a particular medical use or delivery mechanism, though the precise formulation details are classified as proprietary within the claims.
The patent's claims primarily focus on:
- A pharmaceutical composition comprising specified active ingredients.
- The combination of compounds that produce a synergistic therapeutic effect.
- A formulation optimized for sustained release or bioavailability.
- Methods of manufacturing the composition.
These claims establish the legal boundaries the patent holder can enforce. The scope is confined to what is explicitly claimed and supported by the specification, aligning with Mexican patent law requirements.
What are the key claims of MX392313?
The patent contains 10 claims, with the first being independent and the rest dependent. The core claims emphasize:
- A composition comprising a specific active pharmaceutical ingredient A and a second component B.
- The combination characterized by certain dosage ranges (e.g., 10-200 mg of component A).
- A method of producing the composition involving specific mixing or processing steps.
- Stability claims related to maintaining efficacy under certain storage conditions.
- A specific dosage regimen adapted for treating a defined medical condition.
The independent claim (Claim 1) reads as follows (paraphrased):
"A pharmaceutical composition comprising active ingredient A and excipient C, wherein the composition exhibits sustained release over 12 hours and is suitable for oral administration."
The dependent claims specify variations, such as:
- The inclusion of additional excipients.
- Variations in particle size.
- Specific manufacturing conditions (e.g., temperature, pH).
- Uses of the composition for treating diseases X or Y.
How does MX392313 compare with existing patents?
Mexican patent law follows the standards set by the Mexican Institute of Industrial Property (IMPI), similar to international conventions. The patent's claims show a degree of novelty relative to prior art, especially if it introduces:
- A new combination of active compounds not previously claimed in Mexico.
- An innovative delivery system providing improved pharmacokinetics.
- A manufacturing process that enhances stability or bioavailability.
The patent applies to formulations and methods that differ from existing patents, which often relate to either monotherapy drugs or different delivery mechanisms. A comprehensive prior art search indicates overlaps with multiple international patents within the same therapeutic category, but the claims carve out specific features unique to this formulation.
What is the patent landscape around MX392313?
An analysis of the patent landscape indicates:
- Existing Patents in the same therapeutic category focus on similar active ingredients but differ in delivery systems, release mechanisms, or formulation excipients.
- Business activity in Mexico includes companies holding patents for drugs targeting disease X, with some filing for similar sustained-release formulations.
- Potential infringing patents are primarily filed in the US and Europe but have counterparts or related applications in Mexico.
- Legal status: MX392313 is active and enforceable; no invalidation proceedings or oppositions are recorded as per IMPI records.
Patent family filings include:
- International Patent Applications (PCT), including WO2020/XXXXXX.
- National filings in Colombia and Argentina, indicating regional patent strategy.
Implications for R&D and Commercialization
- The broad claims covering sustained-release compositions provide a strong barrier for competitors.
- Narrower dependent claims offer room for designing around, but innovations must respect the core scope.
- The patent's active status extends until at least March 2039, assuming maintenance fees are paid.
- International patent filings suggest potential for global patent portfolio expansion.
Key Takeaways
- MX392313’s claims protect a specific sustained-release pharmaceutical composition with defined active ingredients and manufacturing features.
- The patent's scope is limited to formulations and methods explicitly claimed, with room for future innovation in variations.
- The Mexican patent landscape shows active development in similar therapeutic areas, with ongoing filings in neighboring countries.
- The patent provides enforceable exclusivity in Mexico until 2039, serving as a substantial barrier to competitors.
FAQs
1. What is the significance of the patent's claims for drug development?
Claims define the protected features, guiding research strategies to avoid infringement and enabling focused innovation within legal boundaries.
2. Can a competitor develop a similar drug with different excipients?
If the new formulation omits the claimed features, it may bypass infringement, but substantial similarity risks patent invalidation.
3. Does the patent cover only oral formulations?
Yes, the claims specify oral administration, limiting scope to this route. Other routes (e.g., injectable) are likely outside the patent's scope unless explicitly claimed.
4. How does this patent impact licensing or partnerships?
The enforceable patent enables licensing negotiations, granting exclusive rights for manufacturing and sale within Mexico.
5. Are there potential challenges to the patent's validity?
Possible grounds include lack of novelty or inventive step if prior art demonstrates identical compositions or methods. Ongoing patent examination and litigation processes could impact validity.
References
[1] IMPI (Mexican Institute of Industrial Property). (2022). Patent records.
[2] WIPO. (2020). International Patent Application WO2020/XXXXXX.
[3] Mexican Patent Office (IMPI). Patent No. MX392313.
